SQZB Statistics
Total Valuation
SQZ Biotechnologies Company has a market cap or net worth of 737,278. The enterprise value is 12.02 million.
| Market Cap | 737,278 |
| Enterprise Value | 12.02M |
Important Dates
The next estimated earnings date is Wednesday, March 19, 2025.
| Earnings Date | Mar 19, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
SQZ Biotechnologies Company has 29.49 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 29.49M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 3.08% |
| Owned by Institutions (%) | 13.34% |
| Float | 25.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.06 |
| PB Ratio | 0.39 |
| P/TBV Ratio | 0.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.17 |
| EV / Sales | 0.99 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.16 |
Financial Position
The company has a current ratio of 1.37, with a Debt / Equity ratio of 11.42.
| Current Ratio | 1.37 |
| Quick Ratio | 1.15 |
| Debt / Equity | 11.42 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.29 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -203.37% and return on invested capital (ROIC) is -49.20%.
| Return on Equity (ROE) | -203.37% |
| Return on Assets (ROA) | -41.14% |
| Return on Capital (ROIC) | -49.20% |
| Revenue Per Employee | 228,698 |
| Profits Per Employee | -1.35M |
| Employee Count | 53 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +36.48% in the last 52 weeks. The beta is 1.46, so SQZ Biotechnologies Company's price volatility has been higher than the market average.
| Beta (5Y) | 1.46 |
| 52-Week Price Change | +36.48% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.04 |
| Relative Strength Index (RSI) | 54.94 |
| Average Volume (20 Days) | 8,266 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.65 |
Income Statement
In the last 12 months, SQZ Biotechnologies Company had revenue of 12.12 million and -71.64 million in losses. Loss per share was -2.43.
| Revenue | 12.12M |
| Gross Profit | -39.67M |
| Operating Income | -60.77M |
| Pretax Income | -71.64M |
| Net Income | -71.64M |
| EBITDA | -59.06M |
| EBIT | -60.77M |
| Loss Per Share | -2.43 |
Balance Sheet
The company has 10.19 million in cash and 21.47 million in debt, giving a net cash position of -11.28 million or -0.38 per share.
| Cash & Cash Equivalents | 10.19M |
| Total Debt | 21.47M |
| Net Cash | -11.28M |
| Net Cash Per Share | -0.38 |
| Equity (Book Value) | 1.88M |
| Book Value Per Share | 0.06 |
| Working Capital | 3.26M |
Cash Flow
In the last 12 months, operating cash flow was -74.33 million and capital expenditures -213,000, giving a free cash flow of -74.55 million.
| Operating Cash Flow | -74.33M |
| Capital Expenditures | -213,000 |
| Free Cash Flow | -74.55M |
| FCF Per Share | -2.53 |
Margins
| Gross Margin | n/a |
| Operating Margin | -501.34% |
| Pretax Margin | -591.07% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SQZ Biotechnologies Company does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.56% |
| Shareholder Yield | -3.56% |
| Earnings Yield | -9,739.08% |
| FCF Yield | -10,111.11% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
SQZ Biotechnologies Company has an Altman Z-Score of -21.28. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -21.28 |
| Piotroski F-Score | n/a |